ViiV Healthcare’s Cabenuva and Dovato strategy looks like an ecosystem play as ultra long-acting candidates advance
ViiV Healthcare heads to CROI 2026 with ultra long-acting HIV data for VH4524184, VH4011499 and more. See what it changes next.
Pharma & Biotech
Medical Devices & Diagnostics
bioAffinity Technologies positions CyPath Lung as a confidence tool rather than a diagnostic replacement
Find out how bioAffinity Technologies’ CyPath Lung could reshape decision making for small lung nodules and what risks remain for adoption.
Medical Devices & Diagnostics
Why BIOEMTECH and NorthStar Medical Radioisotopes’ Actinium-225 agreement matters for preclinical alpha therapy development
BIOEMTECH secures Actinium-225 supply from NorthStar. Find out why isotope access now defines radiopharmaceutical development timelines.
Medical Devices & Diagnostics
Why Alcon’s TOTAL30 Multifocal for Astigmatism targets the toughest segment in contact lens care
Alcon has launched TOTAL30 Multifocal for Astigmatism in the U.S. Find out why this matters for presbyopia care and contact lens adoption.
Pharma & Biotech
Why Harmony Biosciences’ pitolisant approval changes the risk calculus in pediatric narcolepsy
FDA approval expands pitolisant into pediatric cataplexy. Explore what this changes for narcolepsy care, safety, and long-term strategy.
Pharma & Biotech
How the Prostate Cancer Foundation’s $6.3m bet on young investigators could shape the next decade of prostate cancer innovation
Discover why the Prostate Cancer Foundation’s $6.3 million investment in young researchers could shape the future of prostate cancer diagnostics and treatment.
Pharma & Biotech
Why Watchmaker Genomics is repurposing CRISPR-Cas9 to reshape NGS library normalization at scale
Watchmaker Genomics is repurposing CRISPR-Cas9 to streamline NGS normalization. Find out why this matters for sequencing at scale.
Pharma & Biotech
Scribe Therapeutics deepens in vivo CRISPR validation with second Eli Lilly collaboration milestone
Scribe Therapeutics hits a second in vivo CRISPR milestone with Eli Lilly. Explore what this changes for gene editing platforms and future therapies.
Pharma & Biotech
Rallybio validates durable complement suppression with RLYB116 in Phase 1 study
Rallybio reports Phase 1 data for RLYB116 showing sustained complement inhibition. Find out what this changes for C5 therapies and what comes next.
Pharma & Biotech
NIM-1324 enters Phase 2 as NImmune Biopharma tests immunometabolism as the next frontier in inflammatory bowel disease
Discover how NImmune Biopharma’s NIM-1324 Phase 2 program could reshape inflammatory bowel disease treatment beyond biologics and JAK inhibitors.